Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data

July 1, 2026 09:29 AM EDT News Briefing An­gi­tia ends Phase 3 in disc dis­ease; Abi­vax tar­gets $800M on col­i­tis da­ta ENDPOINTS 🩻 An­gi­tia Bio­phar­ma­ceu­ti­cals drops Phase 3: The US and Chi­na biotech ter­mi­nat­ed a late-stage tri­al of AGA111 in pa­tients with de­gen­er­a­tive disc dis­ease who had … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER